Antibody-drug conjugates in bladder cancer
Enfortumab vedotin and other ADCs in urothelial cancer.
Key point
Enfortumab vedotin-related adverse events, particularly cutaneous toxicity, were associated with favorable clinical outcomes, but findings are hypothesis-generating and need prospective confirmation.
From: Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis (Clin Genitourin Cancer, 2026 Oct) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 9, 14, 22, 28, 44.
New guidelines and consensus this year
- Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners FoundationESMO Open2026 Aug
- [Management of ocular adverse events associated with antibody-drug conjugates in the treatment of solid tumors: a consensus statement from Chinese experts (2025 edition)]Zhonghua Zhong Liu Za Zhi2026 Mar 23
All papers from the last 12 months
446 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United StatesJ Med Econ2026 DecPMID 42610318
- New and Novel Agents for Advanced Bladder CancerUrol Clin North Am2026 NovPMID 42823054Review
- Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: Current Evidence, Evolving Strategies, and Future DirectionsUrol Clin North Am2026 NovPMID 42823043Review
- Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer Achieving Pathological Complete Response: A Case ReportIJU Case Rep2026 NovPMID 42800938
- Management of extravasations of enfortumab vedotin and pembrolizumab: a case report and mini review of the current literatureJ Cancer Res Clin Oncol2026 Oct 16PMID 42886339Review
- Emerging precision diagnostics in genitourinary cancersExpert Rev Mol Diagn2026 Oct 15PMID 42880770Review
- Nectin-4 and TROP-2 in bladder cancer: biomarkers for targeted therapyPathobiology2026 Oct 15PMID 42879368Review
- Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled TrialsInt J Cancer2026 Oct 15PMID 42050770Systematic review
- Perioperative immune-based treatment for cisplatin-eligible muscle-invasive bladder cancer: a meta-analysis of randomized controlled trialsCrit Rev Oncol Hematol2026 Oct 12PMID 42863770Review
- Re-evaluating Severe Cutaneous Adverse Events to Enfortumab Vedotin: TEC rather than TENJ Am Acad Dermatol2026 Oct 12PMID 42863573
More urology trends
All specialties →Minimally invasive BPH treatments
Water vapour therapy, urethral lift, aquablation and prostatic artery embolisation.
MRI in prostate cancer diagnosis
MRI before biopsy and in screening for prostate cancer.
Transperineal prostate biopsy
Biopsy through the perineum instead of the rectum.
Key point: Transperineal biopsy is the recommended approach when technically feasible.
Thulium fibre laser
Thulium fibre laser for stone lithotripsy and prostate surgery.
Key point: ThuFLEP and conventional HoLEP are clinically comparable, with no definitive superiority of either laser.
PSMA PET in prostate cancer
PSMA PET imaging for staging and recurrence of prostate cancer.
Key point: PSMA-PET/CT is recommended only when PSA exceeds 0.2 μg/L, reporting should follow PSMA-RADS, and it is preferred over lymph-node dissection for staging.
Male infertility
Male infertility and trends in semen quality.
Key point: Male infertility management should be couple-centered, integrating the female partner's reproductive timeline to avoid preventable delays in effective therapy.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(urothelial[tiab] OR bladder[tiab]) AND (enfortumab[tiab] OR "antibody-drug conjugate*"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.